FOR IMMEDIATE RELEASE [Covington, KY~ January 15, 2020]

Bexion Pharmaceuticals, Inc., a clinical stage biotechnology company focused on developing innovative cures for cancer, announced that Dr. Ray Takigiku, Founder and CEO of the Company will present an overview and recent advancements of its lead compound, BXQ-350 in the Immunotherapy Showcase of the PMWC 2020 conference, January 23 at 10:45 am at the Santa Clara Convention Center in Silicon Valley, California.

Dr. Takigiku’s talk will emphasize Bexion’s unique approach to addressing cancer therapeutics, including how its lead compound, BXQ-350 exploits a first-in-class, unique mechanism of action. Bexion believes that innovative therapeutics will create new avenues of stopping disease progression and prolonging patient lives. Key to these innovative therapeutics will be strong safety profiles and demonstrated tumor targeting properties.

About BXQ-350

BXQ-350 is a unique formulation of a synthetically produced, human lysosomal protein, Saposin C (sphingolipid activator protein, or SapC), and the phospholipid dioleoylphosphatidylserine (DOPS).

About Bexion Pharmaceuticals

Bexion Pharmaceuticals is a clinical-stage biopharmaceutical company developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. BXQ-350 has demonstrated pre-clinical antitumor effects in vitro and in vivo, particularly in brain and other solid tumors, including those that may lead to brain metastases.   Bexion has completed a multi-site first-in-human Phase 1 clinical trial of BXQ-350 for solid tumors and gliomas. A Phase 1 Pediatric Trial enrollment was completed in October, 2019.

About PMWC 2020

Established in 2009, PMWC is the largest and original forum for Precision Medicine. Over 2500 attendees including recognized leaders, top global researchers, medical professionals and healthcare/biotech innovators participate in this annual meeting.

 Media Contact: Margaret van Gilse ●859.757.1652 [email protected].

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Bexion’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. Bexion has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Bexion’s need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that Bexion’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. You should not place undue reliance on any forward-looking statements. Bexion undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

Bexion Media